Abstract:Up to now, HSCT has remained the standard and effective therapy for many hematopoietic malignant diseases and some non-malignant hematopoietic diseases. The HLA-matched sibling is the best source of donors; however, such donors are available for only approximately 30% of patients, especially in P.R.China. Virtually almost everyone possesses at least one HLA-haploidentical family donor. However, the use of such donors has presented a major challenge due to graft-versus-host disease (GVHD) and graft rejection. Peking University established a new approach for HLA-mismatched/hapoidentical HSCT using G-CSF primed bone marrow plus G-CSF-mobilized peripheral blood stem cells without ex vivo T cell depletion after the patients were treated with a modified BU/CY2+ATG regimen. Although the result was comparable to that in HLA matched sibling donor transplantation, there are still have room to improve the hemapoeitic/immune reconstitution, reduce the incidence and grade of GVHD further. Mesenchymal stem cell (MSC) is a pluripotent stem cell, supports hematopoeitc progenitors in vitro and posses potent immunosuppressive properties. We hypothesized that cotransplantation of culture-expanded MSCs and hematopoietic stem cells (HSCs) could facilitate engraftment and lessen graft-versus-host disease (GVHD). A phase I study has assessed the safety of contransplantation of MSC, and then a randomized, open-label phase II trial had been conducted in our institution during 2007.6–2008.6. Total twenty-nine patients with leukemia in CR were enrolled in this trial and randomized into study (n=14) or control group (n=15). Three patients in the study group had been found ineligible after randomized: one had relapsed leukemia just before conditioning, another had HLA identical donor and the third one is too overweighed to be infused of enough MSC. The remaining received the G-CSF-mobilized BM and PB from the HLA-mismatched/hapoidentical donor as have been published. Patients in the study group were given culture-expanded MSCs intravenously (3.0–5.0 × 105/kg) from the same donor or health volunteer within 24 hours before infusion of G-BM and PB. Baseline demographic and disease characteristics were balanced between the two groups. MSC infusions were well tolerated, without any infusion-related adverse events. All patients but one in the control group had achieved sustained neutrophil recovery. The median times to neutrophil (absolute neutrophil count ≥0.5 × 109/L) engraftment were 11 days (range, 11–19 days) and 11.5 days (range, 10–23 days) in the study and control groups respectively (p=1.0). There were 2 patients in the control group dead before the platelets engraftment, the median times to platelet recovery (platelet count ≥20 × 109/L ) were 13 days(range 9–52 days) and 19 days (range 10–36 days) (P=0.18). The platelet engraftment was prompted in the study group as for the time to count ≥50 ×109/L (21 days vs 26.5 days, P=0.047). Acute GVHD was observed in 7/11 of patients in study group, 2 had grade I, 5 had grade II. The cumulative incidence of grade II to IV acute GVHD was 48.9%. One patient in the control group had engraftment failure and another was dead of infection on +22 days. Of the thirteen remaining patients, nine patients experienced acute GVHD, 2 had grade I, 6 had grade II and 1 had grade IV. The cumulative incidence of grade II to IV acute GVHD was 61.1%. Our study demonstrated that cotransplantation of culture-expanded MSCs from donor or health volunteer in HLA-haploidentical/mismatched HSCT is feasible and safe. It is seems that MSCs are capable of accelerating hematopoietic cell engraftment, especially for platelet. Further study should be done to reveal whether MSC could reduce the incidence of acute GVHD.

Mesenchymal Stem Cells Enhance the Induction of Mixed Chimerism and Tolerance to Rat Hind-Limb Allografts after Bone Marrow Transplantation

Allogeneic Mesenchymal Stem Cells As Induction Therapy Are Safe and Feasible in Renal Allografts: Pilot Results of a Multicenter Randomized Controlled Trial

Allogeneic bone marrow derived mesenchymal stem cells transplantation leads to stable chimerism and induces donor specific tolerance

Bone Marrow Transplantation Combined with Mesenchymal Stem Cells Induces Immune Tolerance without Cytotoxic Conditioning

Induction of Allogeneic Mixed Chimerism by Immature Dendritic Cells and Bone Marrow Transplantation Leads to Prolonged Tolerance to Major Histocompatibility Complex Disparate Allografts

Effects of chimerism on the mice heart transplanted survival with the bone marrow infusion.

Donor Derived Hematopoietic Stem Cell Niche Transplantation Facilitates Mixed Chimerism Mediated Donor Specific Tolerance.

A Large-Scale Bank of Organ Donor Bone Marrow and Matched Mesenchymal Stem Cells for Promoting Immunomodulation and Transplant Tolerance

Combined Intrathymic and Intravenous Injection of Mesenchymal Stem Cells Can Prolong the Survival of Rat Cardiac Allograft Associated with Decrease in Mir-155 Expression

Long-term (>1 year) analyses of chimerism and tolerance in mixed allogeneic chimeric mice using normal mouse combinations.

Prolongation of allograft survival by donor mesenchymal stem cells infusion in rat heart transplantation

Mixed Chimerism Induces Donor-Specific T-cell Tolerance Across a Highly Disparate Xenogeneic Barrier.

Survival of bone marrow-derived mesenchymal stem cells in a xenotransplantation model.

Migration of Mesenchymal Stem Cells to Heart Allografts During Chronic Rejection

Establishment of a Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Model in Mice and Its Related Study

Enhancement of limb transplantation tolerance induced by infusion of donor bone marrow cell in rats

[Allogenic BMSCs Reverse Chimerism Inducing the Tolerance of Xeno-Skin Graft in Mouse Model].

Dose- And Time-Dependent Effects Of Human Mesenchymal Stromal Cell Infusion On Cardiac Allograft Rejection In Mice

Cotransplantation of Mesenchymal Stem Cells Prompted Platelets Recovery in Hla-Haploidentical/Mismatched Blood and Marrow Transplantation: A Randomized Phase Ii Study

Mesenchymal stem cells administered after liver transplantation prevent acute graft-versus-host disease in rats.

The Knife’s Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but with a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques